Excerpts

In addition, under criterion 1, nodal status was significant, and tumor size demonstrated a trend toward significance ( p = 0.073).

In addition, the statin group showed a trend of higher MMR rates compared to the non-statin group ( p = 0.073) (78.8% vs. 62.6% for MMR at 3 years).

Diffusion parameters did not correlate with clinical outcome, with the exception of ΔADC (%), which showed a trend towards significance ( p = 0.073).

This difference was initially statistically significant ( p = 0.0368) but approached significance after Bonferroni correction ( p = 0.0735).

However, in both the dominant and recessive models, none of the genes were significantly associated with the phenotype ( Table 5 , Figure 2 b,c), although the association with the SLC2A14 gene was marginally significant in the recessive model ( p = 0.07384; Table 5 ).

The use of prior systemic chemotherapy showed an almost significant correlation as an independent variable in this context (HR 1.93, CI 0.94–3.97, p = 0.074).

A comparison of the sites of first metastatic disease among all four CTC change groups revealed differences of borderline significance (Chi-squared test, p = 0.074; Table 3 ).

Bone metastasis showed a trend toward shorter PFS (HR = 2.43; 95% CI, 0.92–6.41; p = 0.074) but did not reach significance for OS (HR = 2.04; 95% CI, 0.63–6.55; p = 0.233) ( Supplementary Table S3, Supplementary Figure S1A,B ). 3.4.

The association showed borderline significance by the Wald test ( p = 0.074) and was supported by the likelihood ratio and score tests ( p = 0.03 and p = 0.04, respectively) ( Table 4 ).

Intratumoural PD-1 status was not associated with OS overall, although PD-1 + AS showed a trend towards poorer survival ( p = 0.0745; Supplementary Figure S4A–D ).

Although patients with postoperative GP73 levels above >85.82 ng/mL showed a strong trend towards an impaired OS, statistical significance was not reached ( p = 0.075, Figure 4 C).

Histopathological aggressiveness features—perineural invasion (PNI; 73.0% in the entire cohort) and vascular invasion (VI; 62.6%)—were relatively evenly distributed, although PNI showed a trend toward a higher incidence in PB (81.8% vs. 63.5% in the PN; p = 0.075), which, however, did not reach significance after adjustment.

A marginally significant correlation between CD8 density and pCR was also observed (50.0% vs. 35.9%, P = 0.075; Figure 3 C).

Surgical delay also showed a trend toward statistical significance as a predictive factor (adjusted OR = 1.04, 95%CI = 0.99–1.08, p = 0.075) ( Table 3 ). 3.4.

In the Checkmate-459, nivolumab failed to demonstrate superiority, despite a positive trend in OS (median OS of 16.4 vs. 14.7 months, HR = 0.85 (95%CI: 13.9–18.4, p = 0.075 for superiority), a better toxicity profile, and improved QoL.

Additionally, a trend toward better PFS was observed in patients with p53 positivity ≥50% (HR: 0.66 [95% CI: 0.40–1.08], p = 0.097), whereas patients harboring L858R showed a trend toward poor outcome (HR: 1.68 [95% CI: 0.95–2.97], p = 0.076).

However, survival in the presence of a single lesion was better than that in the presence of multiple lesions among patients without extracranial metastases, and this survival advantage showed a statistical trend toward significance ( p = 0.076).

Highly positive RIPK3 expression was significantly associated with lower OS (HR 1.697, 95% CI 1.058–2.721, log-rank p = 0.027) and showed a trend toward lower DFS (HR 1.501, 95% CI 0.955–2.361, log-rank p = 0.076) ( Table 2 and Figure 3 ).

We found that patients with PD showed a trend toward higher baseline CTC count (26 ± 36) compared with patients with partial response (14 ± 14) or stable disease (9 ± 26) ( p = 0.076).

CD20 + showed a trend towards better DFS ( p = 0.076).

Although NLR did not reach statistical significance in this cohort, week 1 NLR showed a trend toward prognostic relevance (HR = 2.034, p = 0.076) ( Figure 4 ).

Interestingly, there was a near significance in improved overall survival comparing patients who received neoadjuvant chemotherapy with bevacizumab ( p = 0.0767, Figure 3 ).

There was a trend towards significance when comparing the OS of patients who received neoadjuvant chemotherapy + Bevacizumab ( p = 0.0767) with dHGP patients exhibiting improved overall survival compared with non-dHGP patients ( Figure 3 D).

The presence of existing preoperative trismus approached significance (OR, 2.95; 95% CI, 0.89–9.77; p = 0.077).

In contrast, TP53 mutations demonstrated a strong trend toward increased recurrence risk (OR = 7.0, 95% CI 1.16–135.12; p = 0.077), although this did not reach statistical significance ( Figure 4 B).